InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright

InflaRx (NASDAQ:IFRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright’s price target would indicate a potential upside of 482.52% from the stock’s previous close.

A number of other equities analysts have also commented on the company. Leerink Partnrs lowered InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. Raymond James Financial reaffirmed an “outperform” rating on shares of InflaRx in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 22nd. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down previously from $5.00) on shares of InflaRx in a research note on Wednesday, December 3rd. Finally, Guggenheim increased their price objective on shares of InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

InflaRx Stock Up 1.0%

IFRX traded up $0.01 during midday trading on Tuesday, reaching $1.03. The company had a trading volume of 1,108,669 shares, compared to its average volume of 1,081,028. InflaRx has a 1 year low of $0.71 and a 1 year high of $2.77. The company has a market cap of $69.14 million, a P/E ratio of -1.52 and a beta of 1.46. The business has a 50-day moving average of $1.21 and a two-hundred day moving average of $1.12.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts predict that InflaRx will post -1.04 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently bought and sold shares of IFRX. Cubist Systematic Strategies LLC lifted its stake in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after acquiring an additional 7,616 shares during the period. 683 Capital Management LLC increased its position in InflaRx by 26.8% during the 1st quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company’s stock valued at $2,678,000 after purchasing an additional 555,000 shares during the period. Woodline Partners LP bought a new stake in shares of InflaRx in the 1st quarter valued at about $766,000. Concurrent Investment Advisors LLC purchased a new stake in shares of InflaRx in the 2nd quarter worth approximately $65,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of InflaRx by 158.3% during the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company’s stock valued at $118,000 after purchasing an additional 91,927 shares in the last quarter. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.